Aethlon Medical Inc. Form 8-K Summary
Business Context and Reporting Period
Aethlon Medical, Inc. (AEMD), a Nevada corporation headquartered in San Diego, California, filed this Current Report on Form 8-K on January 22, 2026. The filing addresses corporate actions taken on the same date regarding existing financing arrangements with an institutional investor.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the amendment of legal agreements.
Material Changes
The Company entered into two amendments on January 22, 2026, modifying agreements originally dated December 5, 2025, and December 8, 2025:
- Amendment to Securities Purchase Agreement: Removed the requirement for the Company to obtain shareholder approval under Nasdaq Rule 5635 prior to the issuance or exercise of pre-funded warrants.
- Amendment to Pre-Funded Common Stock Purchase Warrant: Similarly removed the shareholder approval requirement under Nasdaq Rule 5635.
- Result: As a direct consequence of these amendments, the pre-funded warrants are now immediately exercisable.
All other terms of the original Securities Purchase Agreement and Warrant remain unchanged.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the agreement amendments. The document notes that the descriptions of the amendments are brief and qualified by reference to the full text of the agreements attached as Exhibits 10.1 and 10.2.
Investor Verification Checklist
- Verify the full terms of the Amendment to Securities Purchase Agreement (Exhibit 10.1) and Amendment to Pre-Funded Common Stock Purchase Warrant (Exhibit 10.2) to understand any other potential conditions.
- Confirm the total number of pre-funded warrants now immediately exercisable and the associated dilution impact on existing shareholders.
- Review the original December 2025 8-K filings to understand the initial terms of the Securities Purchase Agreement and Warrant.
- Monitor Nasdaq compliance status regarding the removal of the shareholder approval requirement under Rule 5635.